Followers | 234 |
Posts | 26887 |
Boards Moderated | 0 |
Alias Born | 01/12/2013 |
Tuesday, April 15, 2014 2:33:56 PM
FDA/HHS investigation of GSK
John Taylor III; FDA JD
John Taylor III; Biotechnology Industy Oraganization (BIO)
John Taylor III; Abbott, Divisional VP of Federal Government Affs
No longer works at the FDA, Abbott, or BIO Jan 2014 "retired"
Paul Huckle; GSK (Paul Huckle is Chief Regulatory Officer and Senior Vice President for GlaxoSmithKline with worldwide responsibility for managing regulatory affairs)
Feb 2/17/14 – 2/21/14 Meetings with FDA (Elizabeth H. Dickinson, Esq., Chief Counsel & CDER Counsel Denise Esposito
___________________________________________________
Gerald Masoudi (Covington), Paul Huckle (GSK), Elpidio Villarreal (GSK), Jeffrey Jacobson (Debevioise & Plimpton LLP)
Gerald Masoudi is a partner in the firm’s Washington, DC office and co-chair of the Food and Drug practice group.
Before joining Covington in 2009, Mr. Masoudi served as Chief Counsel of the Food and Drug Administration. In that capacity he was responsible for supervising FDA’s involvement in civil and criminal litigation and investigations; providing legal review of warning letters, guidances and regulations; and providing advice to the FDA commissioner and senior leadership on matters relating to the products regulated by FDA. Before joining the FDA, Mr. Masoudi served as Deputy Assistant Attorney General for international, policy and appellate matters in the Antitrust Division at the Department of Justice. He also served as Principal Deputy Chief Counsel for the FDA in 2004 and 2005. Before entering government service, Mr. Masoudi had a decade of experience in private practice in the areas of antitrust, telecommunications, patent law and energy.
-----------------------------------------------------------------
FDA & GSK Meeting on 3-5-2014
FDA Commissioner, Steven Immergut & GSK CEO Witty, Paul Huckle
Margaret A. Hamburg, M.D., Commissioner of Food and Drugs 3/5/14 London, England Steven Immergut Andrew Witty, Paul Huckle (GlaxoSmithKline) Meeting with GlaxoSmithKline (GSK)
Steven Immergut took over for John Taylor III as:
Steven Immergut is the FDA’s Acting Associate Commissioner for External Affairs. In this role, he oversees the planning, development and implementation of agency-wide media communications strategies for disseminating regulatory and educational information to the public through the news media. Mr. Immergut advises the Commissioner and other key agency officials on FDA’s communication to the media and serves as a liaison with the Public Health Service and the Department of Health and Human Services on media activities. Under Mr. Immergut’s leadership, the FDA Office of Media Affairs is the agency’s focal point for preparing, clearing and disseminating press announcements and other statements for the news media, as well as arranging and facilitating press conferences, media briefings, interviews and other news events.
Throughout his extensive career, Mr. Immergut has designed, managed and executed strategic communications initiatives on behalf of organizations operating across the health care sector, including the federal government; pharmaceutical, biotechnology and medical device companies; associations; health care providers; and patient groups.
Immediately prior to joining the FDA, Mr. Immergut was a Senior Associate with the management consulting firm Booz Allen Hamilton, managing government and private sector health communications engagements. Previously, he led the Washington, D.C. Healthcare practice at leading public relations firm Hill+Knowlton Strategies, where he represented a range of clients on medical product and health IT programs and provided counsel on issues management.
Prior to his time at H+K, Mr. Immergut led client engagements for New York-based communications consultancies, Tonic Life Communications and GCI Group, across a wide range of therapeutic categories including oncology, cardiovascular disease, and infectious disease. Mr. Immergut has significant international experience as a healthcare communicator, having represented several global companies based in Europe. And earlier in his career, Mr. Immergut was based in Latin America as consultant under the U.S. Agency for International Development (USAID), working on groundbreaking public health social marketing programs in HIV/AIDS, reproductive health and diarrheal disease.
Mr. Immergut holds a Master of Public Health from George Washington University and a B.S. in marketing from Syracuse University.
Recent AMRN News
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM